United States Diagnostics & Research news

17:22 10 Aug 2026

Medical Product Outsourcing Market update Main company 🇺🇸 United States

bioAffinity Technologies to Add Mexican Patent to its CyPath Lung Technology IP

bioAffinity Technologies Inc. has received notification of patent allowance in Mexico for its CyPath Lung technology, further strengthening its global intellectual property portfolio. This patent protects the use of flow cytometry and specific labeling methods for detecting lung cancer cells in sputum, expanding on …

BIAF main company

Sharemaestro market context Price below Trend Line 52 weeks -92.7% · Next-week setup negative 40.0%

17:02 10 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Sotera Health Company (SHC) Reported Positive Results Amid Litigation Wins

US-based investment company McIntyre Partnerships delivered flat performance in H1 2026, returning 0% gross and -1% net compared to the Russell 2000 Value Index's 23% return. A copy of the letter can be downloaded here. The second quarter results were a complete reversal of …

SHC main company

Sharemaestro market context Trend signal started 52 weeks +19.8%

17:02 10 Aug 2026

nasdaq.com Market update Provider-linked mention 🇺🇸 United States

Stocks Pressured as Higher Crude Price Boosts T-Note Yields

The S&P 500 Index ($SPX) (SPY) today is down -0.04%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.15%. September E-mini S&P futures (ESU26) are down -0.04%, and September E-mini Nasdaq futures (NQU26) …

RDNT mentioned

Sharemaestro market context Price above Trend Line 52 weeks +7.3%

16:40 10 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

CON or MEDP: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own …

MEDP main company

Sharemaestro market context Trend signal started 52 weeks +29.0%

16:38 10 Aug 2026

The Globe and Mail Earnings Provider-linked mention 🇺🇸 United States

Is Labcorp Stock a Buy as Growth Improves but Valuation Stays Rich?

Labcorp (LH) is showing improved revenue growth, wider margins, and higher full-year guidance, particularly in specialty testing and biopharma services. However, its current valuation is considered rich, trading at a premium to its historical median and sub-industry multiple, which raises the bar for future …

DGX mentioned LH mentioned MEDP mentioned

Sharemaestro market context Trend signal active 52 weeks +34.3% · Next-week setup positive 57.4%

16:01 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

3 Growth Stocks with All-Star Potential

3 Growth Stocks with All-Star Potential Growth boosts valuation multiples, but it doesn't always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022. The …

NTRA mentioned

Sharemaestro market context Trend signal active 52 weeks +97.6% · Next-week setup positive 58.3%

15:41 10 Aug 2026

AlphaStreet Earnings Main company 🇺🇸 United States

RadNet Jumps 8.2% on EPS Beat

RadNet shares surged 8.2% after the diagnostic imaging provider reported strong second-quarter earnings. The company posted an EPS of $0.29 on revenue of $622.7 million for the quarter ended June 2026, boosting its market capitalization to $6.0 billion. Investors will be watching if RadNet …

RDNT main company

Sharemaestro market context Price above Trend Line 52 weeks +7.3%

15:39 10 Aug 2026

Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

Revvity, Inc. (RVTY) Stock Forecasts

Morningstar analyst Julie Utterback published a report on Revvity, Inc. (RVTY), a global life sciences and diagnostics company. The report, titled "Revvity Earnings: Strong but Dressed-Up Quarter Boosts 2026 Outlook," was released on August 4, 2026. Revvity operates in life sciences and signals software …

RVTY main company

Sharemaestro market context Trend signal active 52 weeks +26.6%

15:10 10 Aug 2026

PR Newswire Regulatory and legal Main company 🇺🇸 United States

Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky

Levi & Korsinsky is investigating Myriad Genetics (MYGN) for potential securities law violations after the company reported lower-than-expected Q2 2026 revenue, cut its full-year revenue guidance, and suspended adjusted EBITDA guidance. The investigation focuses on whether Myriad Genetics made materially false or misleading statements …

MYGN main company

Sharemaestro market context Price below Trend Line 52 weeks -42.9%

14:47 10 Aug 2026

Clinical Lab Products Regulatory and legal Provider-linked mention 🇺🇸 United States

FDA Advisory Committee to Review GRAIL Multi-Cancer Early Detection Test

The FDA's Molecular and Clinical Genetics Panel will meet on September 23, 2026, to review GRAIL's Premarket Approval application for the Galleri multi-cancer early detection blood test. This test aims to identify cancer-specific methylation patterns before symptoms appear, including for cancers currently without recommended …

DGX mentioned

Sharemaestro market context Trend signal active 52 weeks +34.3% · Next-week setup positive 57.4%

14:40 10 Aug 2026

Simply Wall Street Earnings Main company 🇺🇸 United States

Guardant Health (GH) Is Up 6.1% After Raising 2026 Revenue Outlook And Filing Shelf Registration - Has The Bull Case Changed?

Guardant Health (GH) saw its stock rise 6.1% after increasing its 2026 revenue guidance to US$1.34–1.36 billion, driven by accelerated Shield screening adoption and new UnitedHealth coverage. While the raised outlook strengthens the bull case for sales growth, the company also filed a shelf …

GH main company DGX mentioned LH mentioned

Sharemaestro market context Trend signal active 52 weeks +186.1%

14:22 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇺🇸 United States

PODD's Q2 Earnings Top Estimates, FY'26 Sales View Cut, Stock Down

Insulet Corporation PODD reported second-quarter 2026 adjusted earnings per share (EPS) of $1.66, up 41.5% year over year. The bottom line beat the Zacks Consensus Estimate by 15.28%. GAAP EPS came in at $1.37 compared with the year-ago quarter's figure of 32 cents. Revenues …

DGX mentioned LH mentioned MEDP mentioned

Sharemaestro market context Trend signal active 52 weeks +34.3% · Next-week setup positive 57.4%

14:15 10 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Understanding Qiagen (QGEN) Reliance on International Revenue

Have you assessed how the international operations of Qiagen (QGEN) performed in the quarter ended June 2026? For this diagnostic products maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects. …

QGEN main company

Sharemaestro market context Price above Trend Line 52 weeks -14.7%

14:10 10 Aug 2026

Pluang Regulatory and legal Main company 🇺🇸 United States

Medpace Holdings faces lawsuit over alleged misleading growth info causing inflated stock prices.

Medpace Holdings Inc. is being investigated by Kuehn Law for allegedly misleading shareholders with misrepresented business metrics, including backlog cancellations and growth projections. The lawsuit claims these overly optimistic expectations led investors to purchase stock at inflated prices. Shareholders who bought stock before April …

MEDP main company

Sharemaestro market context Trend signal started 52 weeks +29.0%

14:10 10 Aug 2026

Morningstar Regulatory and legal Main company 🇺🇸 United States

Kuehn Law Encourages Investors of Medpace Holdings, Inc. to Contact Law Firm

Kuehn Law, PLLC is investigating Medpace Holdings, Inc. (NASDAQ: MEDP) for potential breaches of fiduciary duties by its officers and directors. A federal securities lawsuit alleges that Medpace misrepresented its backlog cancellation rates, business conditions, and ability to maintain its projected 1.15 book-to-bill ratio, …

MEDP main company

Sharemaestro market context Trend signal started 52 weeks +29.0%

13:49 10 Aug 2026

seekingalpha.com Market update Provider-linked mention 🇺🇸 United States

High-flyer healthcare stocks: Ten names with strong momentum, weak valuations

[Heart Health Concept] Eoneren/E+ via Getty Images Wall Street investors are increasingly seeking refuge in high-performing equity plays as volatile healthcare markets continue to shift, forcing a critical evaluation of stock price velocity against fundamental underlying valuations. Analysts warn that chasing recent momentum can …

CDNA mentioned

Sharemaestro market context Trend signal active 52 weeks +294.3%

13:40 10 Aug 2026

GuruFocus Analyst action Main company 🇺🇸 United States

BDSX Maintained by Canaccord Genuity -- Price Target Raised to $35

Canaccord Genuity has maintained a 'Buy' rating for Biodesix (BDSX) and increased its price target from $27.00 to $35.00, indicating strong confidence in the company's future. While analysts are optimistic about Biodesix's growth, particularly in medical diagnostics, the stock is considered modestly overvalued according …

BDSX main company

Sharemaestro market context Trend signal active 52 weeks +196.5% · Next-week setup negative 42.9%

13:40 10 Aug 2026

MarketBeat Analyst action Main company 🇺🇸 United States

Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price

Canaccord Genuity Group has increased its price target for Biodesix (NASDAQ:BDSX) to $35 from $27, maintaining a "buy" rating and implying a significant upside of 48.94%. This positive forecast aligns with a "Moderate Buy" consensus rating from other analysts, supported by the company's recent …

BDSX main company

Sharemaestro market context Trend signal active 52 weeks +196.5% · Next-week setup negative 42.9%

13:37 10 Aug 2026

marketscreener.com Analyst action Main company 🇺🇸 United States

TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating

TD Cowen has increased its price target for Charles River Laboratories International (CRL) to $300 from $235, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst updates for the company, indicating positive sentiment following recent financial announcements. The article …

CRL main company

Sharemaestro market context Trend signal active 52 weeks +70.7%

13:34 10 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇺🇸 United States

Beat the Market Like Zacks: Aveanna, FactSet, Shopify in Focus

Last Friday, the three major Wall Street indexes closed a winning week. The Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average gained 5.2%, 3.6% and 3%, respectively. Wall Street's strong weekly performance was driven by renewed investor optimism over the U.S. …

TMO mentioned

Sharemaestro market context Price above Trend Line 52 weeks +21.9%

13:14 10 Aug 2026

Sharemaestro News Company research Main company 🇺🇸 United States

Waters trades 21% above Fair Value as 7.8% week tests conviction near its high

Waters closed at $406.9, just 1.8% below its 52-week high, after a strong week on above-average volume, but the Sharemaestro read remains balanced rather than outright emphatic.

WAT main company

Sharemaestro market context Trend signal active 52 weeks +39.6%

13:06 10 Aug 2026

Stock Traders Daily Market update Main company 🇺🇸 United States

Discipline and Rules-Based Execution in FLGT Response

This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading …

FLGT main company

Sharemaestro market context Price above Trend Line 52 weeks -10.0% · Next-week setup negative 44.2%

13:00 10 Aug 2026

finance.yahoo.com Market update Main company 🇺🇸 United States

Revvity Launches SuperFlex Prenatal Screening System, Expanding Access to Preeclampsia Testing

Revvity's new maternal and fetal biochemistry testing platform Designed for accessibility, simplicity, and flexibility Purpose-built for small to mid-sized labs and clinics to enable this capability in-house for the first time WALTHAM, Mass., August 10, 2026--(BUSINESS WIRE)--Revvity, Inc. today announced the launch of the …

RVTY main company

Sharemaestro market context Trend signal active 52 weeks +26.6%

12:49 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

2 Mid-Cap Stocks to Target This Week and 1 Facing Headwinds

2 Mid-Cap Stocks to Target This Week and 1 Facing Headwinds Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with …

MTD mentioned

Sharemaestro market context Price above Trend Line 52 weeks +8.9% · Next-week setup positive 56.2%

12:41 10 Aug 2026

Radiology Business Deals and strategy Main company 🇺🇸 United States

RadNet touts ‘disproportionately higher’ growth in advanced imaging

RadNet Inc. reported "record" second-quarter results with a 25% year-over-year revenue increase, driven by disproportionately higher growth in advanced imaging procedures like MRI, CT, and PET/CT. The company revised its 2026 financial projections upwards, anticipating greater total net revenue and adjusted earnings, partly due …

RDNT main company

Sharemaestro market context Price above Trend Line 52 weeks +7.3%

12:40 10 Aug 2026

TradingView Market update Main company 🇺🇸 United States

Weekly Recap: Icahn Partners settlement and MiSeq i100 reagent rental

Illumina, Inc. (ILMN) recently settled litigation with Icahn Partners, with the mutual release effective August 21, 2025. Additionally, Illumina expanded its Next-Generation Sequencing (NGS) access in Italy by implementing a multi-year reagent-rental agreement for a MiSeq i100 with Devyser, which shifts capital expenditure to …

ILMN main company

Sharemaestro market context Trend signal active 52 weeks +87.8%

12:39 10 Aug 2026

Stock Titan Earnings Provider-linked mention 🇺🇸 United States

Surgery Partners Reports $15M Q2 Net Loss, Revenue Up 2.7%

Surgery Partners (NASDAQ: SGRY) reported a Q2 2026 net loss of $15.0 million, widening from $2.5 million in the prior year, despite a 2.7% increase in revenue to $848.9 million. Adjusted EBITDA decreased to $125.2 million from $129.0 million, and operating cash flow also …

LH mentioned

Sharemaestro market context Trend signal active 52 weeks +19.3%

12:38 10 Aug 2026

MarketBeat Earnings Main company 🇺🇸 United States

Dudley & Shanley Inc. Has $14.10 Million Position in Danaher Corporation $DHR

Dudley & Shanley Inc. reduced its stake in Danaher Corporation (NYSE:DHR) by 35.6% in Q2, retaining 74,024 shares valued at $14.1 million. Despite this, institutional investors collectively own 79.05% of Danaher, and the company exceeded Q2 earnings expectations with $1.94 EPS and $6.26 billion …

DHR main company

Sharemaestro market context Price above Trend Line 52 weeks -2.2%

12:27 10 Aug 2026

nasdaq.com Analyst action Main company 🇺🇸 United States

Natera Reaches Analyst Target Price

In recent trading, shares of Natera Inc (Symbol: NTRA) have crossed above the average analyst 12-month target price of $100.75, changing hands for $105.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

NTRA main company

Sharemaestro market context Trend signal active 52 weeks +97.6% · Next-week setup positive 58.3%

12:19 10 Aug 2026

Pluang Regulatory and legal Provider-linked mention 🇺🇸 United States

FDA approves Labcorp's PGDx elio® test to identify melanoma patients for targeted BRAF therapies

The FDA has approved Labcorp's PGDx elio® test as a companion diagnostic to identify advanced melanoma patients with specific BRAF mutations. This approval allows clinicians to determine which patients may benefit from targeted BRAF and BRAF/MEK inhibitor therapies, improving treatment options for this deadly …

LH mentioned

Sharemaestro market context Trend signal active 52 weeks +19.3%

12:17 10 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

1 Profitable Stock on Our Buy List and 2 We Find Risky

1 Profitable Stock on Our Buy List and 2 We Find Risky While profitability is essential, it doesn't guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, "Your margin is my opportunity". …

RVTY mentioned

Sharemaestro market context Trend signal active 52 weeks +26.6%

12:14 10 Aug 2026

Investing.com Canada Regulatory and legal Provider-linked mention 🇺🇸 United States

Labcorp wins FDA approval for melanoma companion diagnostic By Investing.com

Labcorp has received FDA approval for its PGDx elio tissue complete CDx, a companion diagnostic for identifying advanced melanoma patients with certain BRAF variants. This test helps clinicians determine eligibility for FDA-approved BRAF inhibitors and combination therapies, offering a crucial treatment option for patients …

LH mentioned

Sharemaestro market context Trend signal active 52 weeks +19.3%

12:10 10 Aug 2026

Simply Wall Street Balance sheet Main company 🇺🇸 United States

Myriad Genetics And 2 Other Promising Penny Stocks For Your Watchlist

This article identifies three promising penny stocks—Myriad Genetics (MYGN), Claros Mortgage Trust (CMTG), and Nextdoor Holdings (NXDR)—that exhibit strong financial health despite current challenges. Myriad Genetics is expanding its market reach through strategic partnerships, Claros Mortgage Trust has a solid cash runway despite unprofitability, …

MYGN main company

Sharemaestro market context Price below Trend Line 52 weeks -42.9%

12:09 10 Aug 2026

Market source Market update Main company 🇺🇸 United States

Labcorp Announces FDA Approval of Companion Diagnostic Supporting Patients with Advanced Melanoma

Labcorp (NYSE: LH) has announced that the FDA approved its PGDx elio® tissue complete CDx as a companion diagnostic. This diagnostic tool helps identify patients with advanced melanoma who have specific BRAF variants, making them eligible for targeted BRAF and BRAF/MEK inhibitor therapies. This …

LH main company

Sharemaestro market context Trend signal active 52 weeks +19.3%

12:07 10 Aug 2026

Bitget Analyst action Main company 🇺🇸 United States

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. : TD COWEN RAISES TARGET PRICE TO $300 FROM $235

TD Cowen has increased its target price for Charles River Laboratories International, Inc. (CRL.N) to $300 from $235. This update reflects a change in the analyst's outlook for the company's stock. The article is a brief news alert from Reuters regarding this financial analyst …

CRL main company

Sharemaestro market context Trend signal active 52 weeks +70.7%

11:59 10 Aug 2026

Stock Titan Market update Provider-linked mention 🇺🇸 United States

For advanced melanoma, Labcorp's test supports access to targeted therapies

Labcorp announced that the FDA has approved its PGDx elio® tissue complete CDx as a companion diagnostic for advanced melanoma. This test identifies specific BRAF V600E/K variants, allowing clinicians to determine which patients may benefit from targeted BRAF and BRAF/MEK inhibitor therapies. The kit-based …

LH mentioned

Sharemaestro market context Trend signal active 52 weeks +19.3%